Condition: KRAS Altered Advanced or Metastatic Solid Tumors · Sponsor: Amgen
The purpose of this first-in-human study is to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary efficacy of AMG 410 when administered alone or in combination with other agents in participants with advanced or metastatic solid tumors harboring KRAS alterations. This is a dose-escalation study in which participants will be assigned to multiple dose levels (DLs) of AMG 410, either as monotherapy or in combination with other agents, followed by expansion cohorts. The goal is to determine the Maximum Tolerated Dose (MTD)-the highest dose with acceptable safety and manageable side effects-or the Recommended Phase 2 Dose (RP2D) of AMG 410 in adult participants with KRAS-altered advanced or metastatic solid tumors.
This description comes directly from the study's public registry record.
Amgen Call Center · 866-572-6436 · medinfo@amgen.com
Always discuss trial participation with your own doctor first.
| City of Hope National Medical Center | Duarte, California, United States | Recruiting |
| University of California Los Angeles | Los Angeles, California, United States | Recruiting |
| Emory University | Atlanta, Georgia, United States | Recruiting |
| Massachusetts General Hospital | Boston, Massachusetts, United States | Recruiting |
| Siteman Cancer Center - Washington University | St Louis, Missouri, United States | Recruiting |
| Duke Cancer Center | Durham, North Carolina, United States | Recruiting |
| Thomas Jefferson University | Philadelphia, Pennsylvania, United States | Recruiting |
| Sarah Cannon Research Institute Oncology Partners | Nashville, Tennessee, United States | Recruiting |
| Next Oncology | San Antonio, Texas, United States | Recruiting |
| Next Virginia | Fairfax, Virginia, United States | Recruiting |
| Chris OBrien Lifehouse | Camperdown, New South Wales, Australia | Recruiting |
| The Queen Elizabeth Hospital | Woodville South, South Australia, Australia | Recruiting |
+ 26 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07094113